News
All
Grid Therapeutics Closes Series A Financing
Read moreGrid Therapeutics Signs Exclusive License to Develop a Novel Immuno-Oncology Antibody
Read moreHuman antibody enhances medication and significantly increases the death of cancer cells
Read moreHuman antibody bolsters cancer drug performance
Read moreNew antibody appears to re-activate immune system in cancer therapy
Read moreEnhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody.
Winkler MT, Bushey RT, Gottlin EB, Campa MJ, Guadalupe ES, Volkheimer
AD, Weinberg JB, Patz EF Jr.
PLoS One. 2017 Jun 28;12(6):e0179841. doi:
10.1371/journal.pone.0179841. eCollection 2017.
PMID: 28658265 [PubMed – in process] Free PMC Article
Read moreAutocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression.
Wang Y, Sun SN, Liu Q, Yu YY, Guo J, Wang K, Xing BC, Zheng QF, Campa
MJ, Patz EF Jr, Li SY, He YW.
Cancer Discov. 2016 Sep;6(9):1022-35. doi:
10.1158/2159-8290.CD-15-1412. Epub 2016 Jun 13.
PMID: 27297552 [PubMed – in process]
Read moreA Therapeutic Antibody for Cancer, Derived from Single Human B Cells.
Bushey RT, Moody MA, Nicely NL, Haynes BF, Alam SM, Keir ST, Bentley
RC, Roy Choudhury K, Gottlin EB, Campa MJ, Liao HX, Patz EF Jr.
Cell Rep. 2016 May 17;15(7):1505-13. doi: 10.1016/j.celrep.2016.04.038.
Epub 2016 May 5.
PMID: 27160908 [PubMed – in process] Free PMC Article
Read more